SNIPR Biome Receives CARB-X Funding to Test...
CMN Briefs
Apr. 22, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Tessera Therapeutics
Main focus: Gene writing for the treatment of genetic diseases
Company stage: Pre-clinical
Diseases (gene editing): Undisclosed
Genome editing tool: Gene writing, mobile genetic elements
Funding stage: Private
Location: Cambridge, MA, USA
Website: https://www.tesseratherapeutics.com/
Tessera Therapeutics is a Flagship Pioneering founded start-up company that focuses on a novel gene-editing technology known as gene writing. Gene writing is based on using mobile genetic elements to make insertions and deletions, and the technology is being developed to address many of the current limitations of existing gene-editing approaches. While the company has not yet disclosed any of its pre-clinical programmes, it has recently raised $230M in a Series B financing.
